Loading…
New and emerging antiarrhythmic and anticoagulant agents for atrial fibrillation
To compare and contrast the pharmacology, efficacy, and safety of new, emerging, and established antiarrhythmic and anticoagulant medications and describe nonpharmacologic interventions for the treatment of atrial fibrillation (AF). Shortcomings of established antiarrhythmic agents include a risk fo...
Saved in:
| Published in: | American journal of health-system pharmacy 2010-05, Vol.67 (9 Supplement 5), p.S26-S34 |
|---|---|
| Main Author: | |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c396t-4712034619ea32bd140b2325f0d3d7d3c4a204cc6aeda2c78a813861004966d73 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c396t-4712034619ea32bd140b2325f0d3d7d3c4a204cc6aeda2c78a813861004966d73 |
| container_end_page | S34 |
| container_issue | 9 Supplement 5 |
| container_start_page | S26 |
| container_title | American journal of health-system pharmacy |
| container_volume | 67 |
| creator | Cheng, Judy W M |
| description | To compare and contrast the pharmacology, efficacy, and safety of new, emerging, and established antiarrhythmic and anticoagulant medications and describe nonpharmacologic interventions for the treatment of atrial fibrillation (AF).
Shortcomings of established antiarrhythmic agents include a risk for proarrhythmias and intolerable adverse effects. Dronedarone is a recently introduced amiodarone congener for maintenance of sinus rhythm after cardioversion in patients with AF that is better tolerated than amiodarone. Vernakalant is an emerging antiarrhythmic agent for conversion of AF to normal sinus rhythm with atrial-selective activity that appears to minimize the risk for proarrhythmia. An unpredictable dose-response relationship and the need for laboratory monitoring are among the many shortcomings of warfarin. Rivaroxaban, an emerging oral direct factor Xa inhibitor, and dabigatran, an emerging oral direct thrombin inhibitor, have predictable dose-response relationships and do not require laboratory monitoring. Additional data from comparative clinical trials will clarify the role of these emerging agents in the treatment of AF. Various nonpharmacologic interventions may be used for rhythm control, rate control, or cardioversion in patients whose AF cannot be managed with pharmacotherapy because of a lack of efficacy or intolerable adverse effects.
New and emerging antiarrhythmic and anticoagulant agents offer advantages over established agents and may improve outcomes in patients with AF. |
| doi_str_mv | 10.2146/ajhp100154 |
| format | article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_733951875</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A231714640</galeid><sourcerecordid>A231714640</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-4712034619ea32bd140b2325f0d3d7d3c4a204cc6aeda2c78a813861004966d73</originalsourceid><addsrcrecordid>eNptkVtLHjEQhkNR6qG96Q-QBS8KwtqcNtm9FLEqiBZsr8N8SXY3kj2YZFn8983Xz1oKkouZTJ4J78yL0BeCzynh4hs89TPBmFT8AzokFatK2mC8l3Msm5Limh6goxifMkJrLD6iA4o5wRVjh-jHvV0LGE1hBxs6N3b5khyE0L-kfnD6z9u2pCfoFp-zAjo7pli0UyggBQe-aN0mOO8huWn8hPZb8NF-fo3H6Nf3q5-XN-Xdw_Xt5cVdqVkjUskloZhxQRoLjG4M4XhDGa1abJiRhmkOWaTWAqwBqmUNNWG1yGPyRggj2TH6uvt3DtPzYmNSg4vaZhWjnZaoJGNNRWpZZfJ0R3bgrXJjO6UAekurC8qIzCvkOFPn71D5GJvXMI22dbn-X8PZrkGHKcZgWzUHN0B4UQSrrS_qny8ZPnlVu2wGa97Qv0ZkgO6A3nX96oJVcQDvM07Vuq5CqkY9LvPss09jUpV6pIL9BrQbmOQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733951875</pqid></control><display><type>article</type><title>New and emerging antiarrhythmic and anticoagulant agents for atrial fibrillation</title><source>Oxford University Press:Jisc Collections:OUP Read and Publish 2024-2025 (2024 collection) (Reading list)</source><creator>Cheng, Judy W M</creator><creatorcontrib>Cheng, Judy W M</creatorcontrib><description>To compare and contrast the pharmacology, efficacy, and safety of new, emerging, and established antiarrhythmic and anticoagulant medications and describe nonpharmacologic interventions for the treatment of atrial fibrillation (AF).
Shortcomings of established antiarrhythmic agents include a risk for proarrhythmias and intolerable adverse effects. Dronedarone is a recently introduced amiodarone congener for maintenance of sinus rhythm after cardioversion in patients with AF that is better tolerated than amiodarone. Vernakalant is an emerging antiarrhythmic agent for conversion of AF to normal sinus rhythm with atrial-selective activity that appears to minimize the risk for proarrhythmia. An unpredictable dose-response relationship and the need for laboratory monitoring are among the many shortcomings of warfarin. Rivaroxaban, an emerging oral direct factor Xa inhibitor, and dabigatran, an emerging oral direct thrombin inhibitor, have predictable dose-response relationships and do not require laboratory monitoring. Additional data from comparative clinical trials will clarify the role of these emerging agents in the treatment of AF. Various nonpharmacologic interventions may be used for rhythm control, rate control, or cardioversion in patients whose AF cannot be managed with pharmacotherapy because of a lack of efficacy or intolerable adverse effects.
New and emerging antiarrhythmic and anticoagulant agents offer advantages over established agents and may improve outcomes in patients with AF.</description><identifier>ISSN: 1079-2082</identifier><identifier>EISSN: 1535-2900</identifier><identifier>DOI: 10.2146/ajhp100154</identifier><identifier>PMID: 20410533</identifier><language>eng</language><publisher>England: American Society of Health-System Pharmacists</publisher><subject>Aged ; Anti-Arrhythmia Agents - adverse effects ; Anti-Arrhythmia Agents - pharmacology ; Anti-Arrhythmia Agents - therapeutic use ; Anti-arrhythmia drugs ; Anticoagulants - adverse effects ; Anticoagulants - pharmacology ; Anticoagulants - therapeutic use ; Atrial fibrillation ; Atrial Fibrillation - drug therapy ; Atrial Fibrillation - therapy ; Atrioventricular Node - surgery ; Catheter Ablation - methods ; Development and progression ; Dosage and administration ; Dose-Response Relationship, Drug ; Drug therapy ; Drugs, Investigational - adverse effects ; Drugs, Investigational - pharmacology ; Drugs, Investigational - therapeutic use ; Humans ; Male ; Models, Cardiovascular ; Pacemaker, Artificial ; Patient outcomes ; Physiological aspects</subject><ispartof>American journal of health-system pharmacy, 2010-05, Vol.67 (9 Supplement 5), p.S26-S34</ispartof><rights>COPYRIGHT 2010 Oxford University Press</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-4712034619ea32bd140b2325f0d3d7d3c4a204cc6aeda2c78a813861004966d73</citedby><cites>FETCH-LOGICAL-c396t-4712034619ea32bd140b2325f0d3d7d3c4a204cc6aeda2c78a813861004966d73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20410533$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cheng, Judy W M</creatorcontrib><title>New and emerging antiarrhythmic and anticoagulant agents for atrial fibrillation</title><title>American journal of health-system pharmacy</title><addtitle>Am J Health Syst Pharm</addtitle><description>To compare and contrast the pharmacology, efficacy, and safety of new, emerging, and established antiarrhythmic and anticoagulant medications and describe nonpharmacologic interventions for the treatment of atrial fibrillation (AF).
Shortcomings of established antiarrhythmic agents include a risk for proarrhythmias and intolerable adverse effects. Dronedarone is a recently introduced amiodarone congener for maintenance of sinus rhythm after cardioversion in patients with AF that is better tolerated than amiodarone. Vernakalant is an emerging antiarrhythmic agent for conversion of AF to normal sinus rhythm with atrial-selective activity that appears to minimize the risk for proarrhythmia. An unpredictable dose-response relationship and the need for laboratory monitoring are among the many shortcomings of warfarin. Rivaroxaban, an emerging oral direct factor Xa inhibitor, and dabigatran, an emerging oral direct thrombin inhibitor, have predictable dose-response relationships and do not require laboratory monitoring. Additional data from comparative clinical trials will clarify the role of these emerging agents in the treatment of AF. Various nonpharmacologic interventions may be used for rhythm control, rate control, or cardioversion in patients whose AF cannot be managed with pharmacotherapy because of a lack of efficacy or intolerable adverse effects.
New and emerging antiarrhythmic and anticoagulant agents offer advantages over established agents and may improve outcomes in patients with AF.</description><subject>Aged</subject><subject>Anti-Arrhythmia Agents - adverse effects</subject><subject>Anti-Arrhythmia Agents - pharmacology</subject><subject>Anti-Arrhythmia Agents - therapeutic use</subject><subject>Anti-arrhythmia drugs</subject><subject>Anticoagulants - adverse effects</subject><subject>Anticoagulants - pharmacology</subject><subject>Anticoagulants - therapeutic use</subject><subject>Atrial fibrillation</subject><subject>Atrial Fibrillation - drug therapy</subject><subject>Atrial Fibrillation - therapy</subject><subject>Atrioventricular Node - surgery</subject><subject>Catheter Ablation - methods</subject><subject>Development and progression</subject><subject>Dosage and administration</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug therapy</subject><subject>Drugs, Investigational - adverse effects</subject><subject>Drugs, Investigational - pharmacology</subject><subject>Drugs, Investigational - therapeutic use</subject><subject>Humans</subject><subject>Male</subject><subject>Models, Cardiovascular</subject><subject>Pacemaker, Artificial</subject><subject>Patient outcomes</subject><subject>Physiological aspects</subject><issn>1079-2082</issn><issn>1535-2900</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNptkVtLHjEQhkNR6qG96Q-QBS8KwtqcNtm9FLEqiBZsr8N8SXY3kj2YZFn8983Xz1oKkouZTJ4J78yL0BeCzynh4hs89TPBmFT8AzokFatK2mC8l3Msm5Limh6goxifMkJrLD6iA4o5wRVjh-jHvV0LGE1hBxs6N3b5khyE0L-kfnD6z9u2pCfoFp-zAjo7pli0UyggBQe-aN0mOO8huWn8hPZb8NF-fo3H6Nf3q5-XN-Xdw_Xt5cVdqVkjUskloZhxQRoLjG4M4XhDGa1abJiRhmkOWaTWAqwBqmUNNWG1yGPyRggj2TH6uvt3DtPzYmNSg4vaZhWjnZaoJGNNRWpZZfJ0R3bgrXJjO6UAekurC8qIzCvkOFPn71D5GJvXMI22dbn-X8PZrkGHKcZgWzUHN0B4UQSrrS_qny8ZPnlVu2wGa97Qv0ZkgO6A3nX96oJVcQDvM07Vuq5CqkY9LvPss09jUpV6pIL9BrQbmOQ</recordid><startdate>20100501</startdate><enddate>20100501</enddate><creator>Cheng, Judy W M</creator><general>American Society of Health-System Pharmacists</general><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20100501</creationdate><title>New and emerging antiarrhythmic and anticoagulant agents for atrial fibrillation</title><author>Cheng, Judy W M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-4712034619ea32bd140b2325f0d3d7d3c4a204cc6aeda2c78a813861004966d73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Aged</topic><topic>Anti-Arrhythmia Agents - adverse effects</topic><topic>Anti-Arrhythmia Agents - pharmacology</topic><topic>Anti-Arrhythmia Agents - therapeutic use</topic><topic>Anti-arrhythmia drugs</topic><topic>Anticoagulants - adverse effects</topic><topic>Anticoagulants - pharmacology</topic><topic>Anticoagulants - therapeutic use</topic><topic>Atrial fibrillation</topic><topic>Atrial Fibrillation - drug therapy</topic><topic>Atrial Fibrillation - therapy</topic><topic>Atrioventricular Node - surgery</topic><topic>Catheter Ablation - methods</topic><topic>Development and progression</topic><topic>Dosage and administration</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug therapy</topic><topic>Drugs, Investigational - adverse effects</topic><topic>Drugs, Investigational - pharmacology</topic><topic>Drugs, Investigational - therapeutic use</topic><topic>Humans</topic><topic>Male</topic><topic>Models, Cardiovascular</topic><topic>Pacemaker, Artificial</topic><topic>Patient outcomes</topic><topic>Physiological aspects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cheng, Judy W M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of health-system pharmacy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cheng, Judy W M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New and emerging antiarrhythmic and anticoagulant agents for atrial fibrillation</atitle><jtitle>American journal of health-system pharmacy</jtitle><addtitle>Am J Health Syst Pharm</addtitle><date>2010-05-01</date><risdate>2010</risdate><volume>67</volume><issue>9 Supplement 5</issue><spage>S26</spage><epage>S34</epage><pages>S26-S34</pages><issn>1079-2082</issn><eissn>1535-2900</eissn><abstract>To compare and contrast the pharmacology, efficacy, and safety of new, emerging, and established antiarrhythmic and anticoagulant medications and describe nonpharmacologic interventions for the treatment of atrial fibrillation (AF).
Shortcomings of established antiarrhythmic agents include a risk for proarrhythmias and intolerable adverse effects. Dronedarone is a recently introduced amiodarone congener for maintenance of sinus rhythm after cardioversion in patients with AF that is better tolerated than amiodarone. Vernakalant is an emerging antiarrhythmic agent for conversion of AF to normal sinus rhythm with atrial-selective activity that appears to minimize the risk for proarrhythmia. An unpredictable dose-response relationship and the need for laboratory monitoring are among the many shortcomings of warfarin. Rivaroxaban, an emerging oral direct factor Xa inhibitor, and dabigatran, an emerging oral direct thrombin inhibitor, have predictable dose-response relationships and do not require laboratory monitoring. Additional data from comparative clinical trials will clarify the role of these emerging agents in the treatment of AF. Various nonpharmacologic interventions may be used for rhythm control, rate control, or cardioversion in patients whose AF cannot be managed with pharmacotherapy because of a lack of efficacy or intolerable adverse effects.
New and emerging antiarrhythmic and anticoagulant agents offer advantages over established agents and may improve outcomes in patients with AF.</abstract><cop>England</cop><pub>American Society of Health-System Pharmacists</pub><pmid>20410533</pmid><doi>10.2146/ajhp100154</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1079-2082 |
| ispartof | American journal of health-system pharmacy, 2010-05, Vol.67 (9 Supplement 5), p.S26-S34 |
| issn | 1079-2082 1535-2900 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733951875 |
| source | Oxford University Press:Jisc Collections:OUP Read and Publish 2024-2025 (2024 collection) (Reading list) |
| subjects | Aged Anti-Arrhythmia Agents - adverse effects Anti-Arrhythmia Agents - pharmacology Anti-Arrhythmia Agents - therapeutic use Anti-arrhythmia drugs Anticoagulants - adverse effects Anticoagulants - pharmacology Anticoagulants - therapeutic use Atrial fibrillation Atrial Fibrillation - drug therapy Atrial Fibrillation - therapy Atrioventricular Node - surgery Catheter Ablation - methods Development and progression Dosage and administration Dose-Response Relationship, Drug Drug therapy Drugs, Investigational - adverse effects Drugs, Investigational - pharmacology Drugs, Investigational - therapeutic use Humans Male Models, Cardiovascular Pacemaker, Artificial Patient outcomes Physiological aspects |
| title | New and emerging antiarrhythmic and anticoagulant agents for atrial fibrillation |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T05%3A38%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20and%20emerging%20antiarrhythmic%20and%20anticoagulant%20agents%20for%20atrial%20fibrillation&rft.jtitle=American%20journal%20of%20health-system%20pharmacy&rft.au=Cheng,%20Judy%20W%20M&rft.date=2010-05-01&rft.volume=67&rft.issue=9%20Supplement%205&rft.spage=S26&rft.epage=S34&rft.pages=S26-S34&rft.issn=1079-2082&rft.eissn=1535-2900&rft_id=info:doi/10.2146/ajhp100154&rft_dat=%3Cgale_proqu%3EA231714640%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c396t-4712034619ea32bd140b2325f0d3d7d3c4a204cc6aeda2c78a813861004966d73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=733951875&rft_id=info:pmid/20410533&rft_galeid=A231714640&rfr_iscdi=true |